Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Pre-Tax Margin

Income before tax as a percentage of revenue.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin widens to 8.9%

Pre-tax margin was 8.9% in Q2 FY2026, up 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 6.5%, up 3.3 pp year over year. Over 3 fiscal years it widened by 15.8 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
8.9%-2.2 pp QoQ
Last fiscal yearDec 2025
4.6%+6.6 pp YoY
LTMJun 2026
6.5%+3.3 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.8 pp——
1 year+6.6 pp——
3 years+15.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
4.6%
Year-over-year change
+6.6pp

Pre-Tax Margin vs competitors

How AMRX compares with its peers on the latest reported figures

  • AMRX's LTM Jun 2026 pre-tax margin of 6.5% is the 5th highest of the 11 companies compared; the peer median is 2.3%.
  • Its year-over-year change of +3.3 pp is the 6th highest of 11, against a peer median of -2.3 pp.
  • Over three fiscal years its change of +15.8 pp compares with a peer median of +6.1 pp.
AMRX Competitors Peer median
Pre-Tax Margin for AMRX and competitors
Company Period LTM level YoY 3-year change
INDVIndivior Pharmaceuticals IncLTM Jun 202629.5% +11.8 pp+29.2 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202614.3% -9.5 pp-5.8 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202612.6% +16.6 pp+30.7 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 202610.6% -11.6 pp-8.2 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 20266.5% +3.3 pp+15.8 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20264.2% +4.6 pp+28.2 pp
EBSEmergent BioSolutions Inc.LTM Mar 20260.5% +7.0 pp+30.7 pp
VTRSViatris Inc.LTM Jun 2026-4.5% +22.1 pp-42.9 pp
BHCBausch Health Companies Inc.LTM Jun 2026-6.7% -9.6 pp+5.2 pp
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-17.2% -9.1 pp+6.9 pp
PRGOPerrigo Company plcLTM Jun 2026-38.9% -41.3 pp-27.4 pp
Peer median (excluding AMRX) 2.3%-2.3 pp+6.1 pp

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.